255 related articles for article (PubMed ID: 34290161)
1. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
2. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
3. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
4. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
[TBL] [Abstract][Full Text] [Related]
5. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
6. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
[TBL] [Abstract][Full Text] [Related]
8. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
Pijpers J; den Boer ML; Essink DR; Ritmeijer K
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
11. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM; Ismael A
Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164
[TBL] [Abstract][Full Text] [Related]
12. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
14. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
15. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
16. Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
Das VNR; Siddiqui NA; Bhunia GS; Pandey K; Sinha SK; Ansari MZ; Topno RK; Lal CS; Ranjan A; Singh VP; Das P
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009598. PubMed ID: 34428232
[TBL] [Abstract][Full Text] [Related]
17. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
18. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Sundar S; Singh A; Chakravarty J; Rai M
ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
[TBL] [Abstract][Full Text] [Related]
20. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
